As per the results of a large scale survey conducted across India, over 43 percent of the respondents who had diabetes in 2021 were above 60 years of age. Notably, about 3.3 percent of respondents in the 20 to 29 year old age bracket also reported to have diabetes that year. This was a worrying trend and was linked with an unhealthy lifestyle.

According to a survey conducted between 2019 and 2021 in India, about four percent each among men and women, aged 35 to 49 years reported having diabetes. During the same time period, Indians between 15 and 19 years old had the lowest prevalence of diabetes.

As per the results of a large scale survey conducted across India, almost 18 percent of the respondents who had diabetes in 2021 were from the city of Bhopal. This was followed by almost 17.6 percent of diabetic respondents from Chennai and more around 16.7 percent from Bhubaneshwar that year. This was a worrying trend and was linked with an unhealthy lifestyle.

As per the results of a large scale survey conducted across India, 13.2 percent of the respondents had diabetes in 2021. This was an increase in the share of people with diabetes compared to the previous years of the survey. Overall, lifestyle diseases like diabetes, thyroid and blood pressure were seen to be rising among Indians.

India IN: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Female data was reported at 19.800 NA in 2016. This records a decrease from the previous number of 20.000 NA for 2015. India IN: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Female data is updated yearly, averaging 21.200 NA from Dec 2000 (Median) to 2016, with 5 observations. The data reached an all-time high of 23.400 NA in 2000 and a record low of 19.800 NA in 2016. India IN: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Female data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s India – Table IN.World Bank.WDI: Health Statistics. Mortality from CVD, cancer, diabetes or CRD is the percent of 30-year-old-people who would die before their 70th birthday from any of cardiovascular disease, cancer, diabetes, or chronic respiratory disease, assuming that s/he would experience current mortality rates at every age and s/he would not die from any other cause of death (e.g., injuries or HIV/AIDS).; ; World Health Organization, Global Health Observatory Data Repository (http://apps.who.int/ghodata/).; Weighted average;

BackgroundThe young Indian population, which constitutes 65% of the country, is fast adapting to a new lifestyle, which was not known earlier. They are at a high risk of the increasing burden of diabetes and associated complications. The new evolving lifestyle is not only affecting people’s health but also mounting the monetary burden on a developing country such as India.AimWe aimed to collect information regarding the prevalence of risk of diabetes in young adults ( 60), moderate (IDRS score 30–50), and low (IDRS < 30) diabetes risk in young adults (

According to a survey conducted between 2019 and 2021 in India, the prevalence of diabetes was highest in the southern states of Kerala and Goa. It was reported by 4.1 percent of respondents in each state. At the same time, about four percent of respondents in the union territory of Puducherry had diabetes.

The size of the Diabetes Industry in India market was valued at USD XXX Million in 2023 and is projected to reach USD XXX Million by 2032, with an expected CAGR of 3.50% during the forecast period.A disease characterized by chronic high sugar blood levels is called diabetes, due either to deficiency or incapability of the body to function correctly regarding insulin production and utilization within this person's body. Serious conditions diabetes can cause include heart failure and stroke, renal failure or kidney failure, blindness due to the presence of damaged nerves in one's retina area.India has emerged as the world's diabetes capital, with millions of people suffering from this chronic condition. The growing prevalence of diabetes in India is mainly due to lifestyle-related factors such as urbanization, sedentary lifestyle, and unhealthy dietary habits. Consequently, the incidence of diabetes has led to a rapid expansion in the Indian diabetes market.The Indian diabetes industry includes a variety of products and services, including anti-diabetic drugs, insulin delivery devices, blood glucose monitoring systems, and other related medical devices.Multinational pharmaceutical companies have a market lead in offering various types of insulin and oral diabetes medications, though local players are becoming more and more important for the Indian diabetes market, particularly for the affordable generic drug category. Recent developments include: March 2023: Sanofi (India) has recently obtained marketing authorization from the Central Drugs Standard Control Organization (CDSCO) for its diabetes medication, Soliqua™. This pre-filled pen drug is specifically designed to enhance glycemic control in adults with type 2 diabetes and obesity who have not achieved sufficient control through oral or injectable therapies. Soliqua™ is administered once daily through pre-filled pens, containing a fixed-ratio combination of insulin glargine and lixisenatide in two different ratios (10-40 and 30-60)., November 2022: AstraZeneca India gets approval to market the anti-diabetes drug Dapagliflozin. The company said it had received approval from the Central Drugs Standard Control Organization (CDCSCO) for the drug indicated for diabetes patients with chronic kidney disease (CKD).. Key drivers for this market are: Increasing Geriatric Population and Changing Dietary Habits, High Prevalence of Irritable bowel syndrome with constipation (IBS-C) and Opioid-induced constipation (OIC) and Chronic Constipation; Development of Latest Drugs and Treatment Procedures. Potential restraints include: Increasing Dependence on Majority of Over-the-Counter (OTC) Drugs, Lack of Awareness and Reluctance Among Patients due to Adverse Effects of Opioid-Induced Constipation (OIC) Drugs. Notable trends are: Oral-Anti Diabetes Drugs Segment is Having the Highest Market Share in the Current Year.

The India diabetes market size was valued at INR 316.00 Billion in 2024, driven by high prevalence of diabetes cases across the region. The market is expected to grow at a CAGR of 16.00% during the forecast period of 2025-2034, to reach INR 1394.01 Billion by 2034.

Snapshot img

Type 2 Diabetes Market Size 2025-2029

The type 2 diabetes market size is forecast to increase by USD 53.8 billion at a CAGR of 12.2% between 2024 and 2029.

The market is experiencing significant growth due to several key factors. The rising prevalence of diabetes, driven by unhealthy lifestyles and an aging population, is a major growth driver. Additionally, the low diagnosis rate presents an opportunity for market expansion. It is administered via different routes, including subcutaneous injection, insulin pumps, and insulin pens. According to the American Diabetes Association, approximately 26.8 million people in the United States have diabetes, and 7.3 million are undiagnosed. With increasing awareness and advancements in diagnostic tools, this number is expected to increase. These include continuous glucose monitoring systems, closed-loop insulin delivery systems, and non-pharmacological interventions such as diet and exercise. Furthermore, the growing burden of diabetes on healthcare systems and the need for effective management solutions are creating new opportunities for market participants. Overall, the market is poised for growth in the coming years, driven by these key trends and challenges.

What will be the Size of the Type 2 Diabetes Market During the Forecast Period?

Request Free Sample

The market encompasses a range of therapeutic compounds designed to manage and mitigate the effects of this chronic condition. With a global prevalence estimated to affect over 463 million people, primarily adolescents and young adults, the market exhibits significant growth due to the increasing burden of cardiovascular diseases, renal problems, and neurological complications associated with hyperglycemia. These complications include heart diseases, damage to the kidneys, and eye disorders, among others. Insulin and non-insulin medications, such as Jardiance, Tanzeum, and Trulicity, are commonly used to regulate blood sugar levels and alleviate symptoms like increased thirst, urination, fatigue, blurred vision, slow-healing wounds, and infections. Additionally, patients may experience tingling, numbness in feet and hands, and other neurological issues. Pharmaceutical companies continue to invest in research and development to address the unmet needs of this patient population and improve overall quality of life.

How is this Type 2 Diabetes Industry segmented and which is the largest segment?

The type 2 diabetes industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Drug Class

  Insulin
  DPP-4 inhibitor
  GLP-1 receptor agonists
  SGLT-2 inhibitors
  Others


Distribution Channel

  Retail pharmacies
  Hospital pharmacies
  Online pharmacies


Delivery Mode

  Oral
  Injectable
  Continuous glucose monitoring (CGM)


Geography

  North America

    Canada
    US


  Europe

    Germany
    UK
    France
    Italy


  Asia

    China
    India
    Japan
    South Korea


  Rest of World (ROW)

By Drug Class Insights

The insulin segment is estimated to witness significant growth during the forecast period.

Type 2 diabetes is a chronic metabolic disorder characterized by insulin resistance and high blood glucose levels. This condition affects adolescents, teenagers, and young adults, leading to increased thirst, urination, fatigue, blurred vision, slow-healing wounds, infections, tingling, numbness in feet and hands, yeast infections, darkened skin areas, and neurological problems. Over time, high blood glucose levels can lead to cardiovascular diseases, renal problems, and damage to the eyes. Insulin, a peptide hormone, plays a crucial role in regulating blood glucose levels. It interacts with insulin receptors on cell surfaces, facilitating the absorption of glucose into the cells. Insulin deficiency or insulin resistance leads to hyperglycemia, which can result in complications. The market for therapeutic compounds to manage Type 2 diabetes includes various drug classes such as insulin, thiazolidinediones, PPAR receptors agonists, Dipeptidyl Peptidase-4 Inhibitors, Alpha-Glucosidase Inhibitors, Sulfonylureas, Secretagogues, Biguanides, and others.

Moreover, these medications help improve glycemic control, reduce cardiovascular risk, and avoid hypoglycemia. Insulin is available in various forms, including human insulin, analog insulins, and inhaled insulin. Retail pharmacies and online pharmacies offer convenience for patients to access insulin and other diabetes medications. The market for Type 2 diabetes medications is expected to grow significantly due to the increasing prevalence of the disease and the need for effective disease management. Emerging economies are expected to offer significant growth opportunities due to increasin

India IN: Prevalence of Overweight: Weight for Height: % of Children Under 5, Modeled Estimate data was reported at 2.800 % in 2022. This records an increase from the previous number of 2.700 % for 2021. India IN: Prevalence of Overweight: Weight for Height: % of Children Under 5, Modeled Estimate data is updated yearly, averaging 2.300 % from Dec 2000 (Median) to 2022, with 23 observations. The data reached an all-time high of 2.800 % in 2022 and a record low of 2.200 % in 2015. India IN: Prevalence of Overweight: Weight for Height: % of Children Under 5, Modeled Estimate data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s India – Table IN.World Bank.WDI: Social: Health Statistics. Prevalence of overweight children is the percentage of children under age 5 whose weight for height is more than two standard deviations above the median for the international reference population of the corresponding age as established by the WHO's 2006 Child Growth Standards.;UNICEF, WHO, World Bank: Joint child Malnutrition Estimates (JME).;Weighted average;Once considered only a high-income economy problem, overweight children have become a growing concern in developing countries. Research shows an association between childhood obesity and a high prevalence of diabetes, respiratory disease, high blood pressure, and psychosocial and orthopedic disorders (de Onis and Blössner 2003). Childhood obesity is associated with a higher chance of obesity, premature death, and disability in adulthood. In addition to increased future risks, obese children experience breathing difficulties and increased risk of fractures, hypertension, early markers of cardiovascular disease, insulin resistance, and psychological effects. Children in low- and middle-income countries are more vulnerable to inadequate nutrition before birth and in infancy and early childhood. Many of these children are exposed to high-fat, high-sugar, high-salt, calorie-dense, micronutrient-poor foods, which tend be lower in cost than more nutritious foods. These dietary patterns, in conjunction with low levels of physical activity, result in sharp increases in childhood obesity, while under-nutrition continues. Estimates are modeled estimates produced by the JME. Primary data sources of the anthropometric measurements are national surveys. These surveys are administered sporadically, resulting in sparse data for many countries. Furthermore, the trend of the indicators over time is usually not a straight line and varies by country. Tracking the current level and progress of indicators helps determine if countries are on track to meet certain thresholds, such as those indicated in the SDGs. Thus the JME developed statistical models and produced the modeled estimates.

BackgroundIndia is witnessing an epidemic of type 2 diabetes. Overweight/obesity, overnutrition, physical inactivity, and family history are well-known risk factors for diabetes. We investigated the role of undernutrition in the development of diabetes among rural adolescent girls.MethodsDERVAN cohort study was set up in the KONKAN region of the western Indian state of Maharashtra. It enrolled 1,520 adolescent girls (16–18 years old at the time of enrollment). We measured glycemic parameters (glucose, insulin, and HbA1C) and body size using anthropometry and body composition using bioimpedance. Prediabetes was diagnosed using the American Diabetic Association (ADA) criteria. We also calculated various HOMA indices for insulin resistance (HOMA-IR), β-cell function (HOMA-β), insulin sensitivity (HOMA-S), and compensatory β-cell response using a homeostasis model. BMI, body fat%, and waist circumferences were treated as exposures and all the glycemic parameters and indices as outcomes.ResultsThe median age of the subjects was 16.6 years. The median weight, height, and BMI were 40.7 kg, 151.7 cm, and 17.5 kg/m2, respectively. Prevalence of underweight was 28.8%, and stunting was observed in 30.4%. Thinness and obesity using BMI were observed in 58.4% and 4.2%, respectively. The median body fat% was 22.5, and excess body fat (>35%) was observed in 5.7%. The prevalence of prediabetes was 39.4%. Fasting insulin concentrations, HOMA-IR, and HOMA-β showed a positive trend across body composition quartiles (p < 0.001). HOMA-S and compensatory β-cell response showed an inverse trend (p < 0.001). Compared with prediabetic girls in the overweight/obese group, girls most undernourished group had lower median insulin concentrations (8.1 μIU/ml vs. 17.1 μIU/ml), lower HOMA-IR (1.1 vs. 2.3), and lower HOMA-β (75.6 vs. 129.2) but higher sensitivity (87.4 vs. 43.7) (p < 0.001) for all.ConclusionWe have reported a high prevalence of prediabetes among rural adolescent girls with a very low prevalence of obesity. Prediabetes in obesity is driven by hyperinsulinemia and overworking of the pancreas while poor β-cell function and poor insulin secretion are major drivers in the undernourished group. The high-risk diabetes screening programs are much needed for the undernourished populations. Caution should be exercised for planning the interventions as overfeeding (or overnutrition) is likely to put the populations at risk of development of obesity and insulin resistance.

This statistic represents the prevalence of diabetes among males across India in 2016, by age group. Men between 75 and 79 years old had diabetes prevalence of 19.9 percent, the highest share among other age groups during the measured time period.

This statistic represents the number of cases of diabetes in senior citizens across India from 2011 to 2050. The number of cases of diabetes in senior citizens across India in 2050 was forecasted to be about 33.3 million.

BackgroundHealth of migrants is a major public health challenge faced by governments and policy makers. Asian Indians are among the fastest growing migration groups across Asia and the world, but the impact of migration and acculturation on diabetes and diabetes-related eye complications among Indians living in urban Asia remains unclear. Methodologies/Principal FindingsWe evaluated the influence of migration and acculturation (i.e., migration status and length of residence) on the prevalence of type-2 diabetes mellitus (T2DM) and diabetes-related eye complications (diabetic retinopathy (DR) and cataract), among first-generation (defined as participant born in India with both parents born in India, n = 781) and second-generation (participants born in Singapore with both parents born in India, n = 1,112) Indian immigrants from a population-based study of Adult Indians in Singapore. Diabetes was defined as HbA1c≥6.5%, use of diabetic medication or a physician diagnosis of diabetes. Retinal and lens photographs were graded for the presence of DR and cataract. Compared to first generation immigrants, second generation immigrants had a higher age- and gender-standardized prevalence of T2DM (34.4% versus 29.0%, p

Background: Australia has a high proportion of migrants with an increasing migration rate from India. Type II diabetes is a long-term condition common amongst the Indian population.Aims: To investigate patients’ medication-taking behaviour and factors that influence adherence at the three phases of adherence.Methods: Semi-structured interviews were conducted with a convenience sample of 23 Indian migrants living in Sydney. All interviews were audio-recorded, transcribed verbatim and thematically analysed.Results: 1) Initiation: The majority of participants were initially prescribed oral antidiabetic medicine and only two were started on insulin. Most started taking their medicine immediately while some delayed initiating therapy due to fear of side-effects. 2) Implementation: Most participants reported taking their medicine as prescribed. However, some reported forgetting their medicine especially when they were in a hurry for work or were out for social events. 3) Discontinuation: A few participants discontinued taking their medicine. Those who discontinued did so to try Ayurvedic medicine. Their trial continued for a few weeks to a few years. Those who did not receive expected results from the Ayurvedic medicine restarted their prescribed conventional medicine.Conclusion: A range of medication-taking behaviours were observed, ranging from delays in initiation to long-term discontinuation, and swapping of prescribed medicine with Ayurvedic medicine. This study highlights the need for tailored interventions, including education, that focus on factors that impact medication adherence from initiation to discontinuation of therapy.

The India Insulin Pumps Market size is projected to exhibit a growth rate (CAGR) of 7.90% during 2025-2033. The growing demand for effective diabetes management solutions, along with the collaborations between manufacturers and local distributors, are among the key factors driving the market.

IMARC Group provides an analysis of the key trends in each segment of the India insulin pumps market report, along with forecasts at the country and regional levels for 2025-2033. Our report has categorized the market based on product type and distribution channel.

Product Type:Reagents & KitsInstruments (Bench Top Devices and Hand-Held Devices)Technology:Ion-Exchange HPLCImmunoassayBoronate Affinity HPLCEnzymatic AssayTurbidimetric Inhibition Immunoassay (TINIA)Application:ThalassemiaSickle Cell AnaemiaType 2 DiabetesEnd User:Hospitals and ClinicsDiagnostic LaboratoriesOthers (Research Institutes, Home Care Settings) Recent developments include: February 2022: Abbott (US) moved into collaboration with health-tech partners BeatO (India), PharmEasy (India), Sugar.fit (India), GOQii (India), Zyla Health (India), 1MG (India), Healthifyme (India), and Fitterfly (India) to lead a new era of holistic diabetes management. Through these collaborations, Abbott aims to offer glucose monitoring solutions to 8 million people living with diabetes, of which around 6.5 million users can access through 1MG and PharmEasy., March 2020: PTS Diagnostics (US) launched the A1CNow+ Controls for the A1CNow+ Test System. A1CNow+ Controls can be kept at room temperature for seven days, in the refrigerator for eight months, or in the freezer for up to three years. Within minutes, both solution’s levels each in a dropper-style vial can be used. Its goal is to ensure accurate A1C measurements. Customers can buy this product from the US, EU, UK, and including India.. Key drivers for this market are: RISING PREVALENCE OF TYPE 2 DIABETES, INCREASED PREVALENCE OF THALASSEMIA AND SICKLE CELL AMONG INDIA. Potential restraints include: HIGH COST OF HBA1C TESTING. Notable trends are: Increased prevalence of thalassemia and sickle cell among India.

Market Size and Growth: The global combination drugs market for diabetes is projected to reach USD 1.09 million by 2033, growing at a CAGR of 10.87% from 2025-2033. Key drivers include rising diabetes prevalence, increasing demand for combination therapies, and favorable government policies. The market is segmented into oral and insulin combination drugs, with oral combination drugs holding the larger share. Competitive Landscape and Trends: Novo Nordisk A/S, Merck, Sanofi, and Eli Lilly are the leading players in the combination drugs market for diabetes. These companies hold significant market shares and are continuously investing in research and development to expand their product portfolios. The market is expected to witness increased mergers and acquisitions as companies seek to strengthen their positions. Additionally, advancements in technology, such as the development of continuous glucose monitors and artificial pancreas systems, are expected to drive market growth in the coming years. Recent developments include: July 2022: Glenmark Pharmaceuticals Limited announced that it had launched sitagliptin and its fixed-dose combinations for adults with Type 2 diabetes in India. Glenmark introduced 8 different combinations of sitagliptin-based drugs under the brand name SITAZIT and its variants at an affordable price., July 2022: European Commission released the Commission Implementing Decision granting marketing authorization under Regulation (EC) No 726/2004 of the European Parliament and the Council for "Sitagliptin/Metformin hydrochloride Accord - sitagliptin / metformin hydrochloride.". Notable trends are: Janumet holds the highest market share in the Combination Anti-Diabetes Drugs Market in the current year.

This statistic represents the prevalence of diabetes among females in India in 2016, by age group. Women between 75 and 79 years old had a share of 16.4 percent, accounting for the highest share of diabetes prevalence during the measured time period.